Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

CDx for Agios Cancer Candidate to Be Developed by Thermo Fisher Scientific

Agios’ Pharmaceuticals’ Phase III cancer candidate ivosidenib (AG-120) will have a next-generation sequencing (NGS) companion diagnostic (CDx) developed and ...

Forward this item to a colleague:


(Separate multiple addresses by commas)